OV E R V I E W A N D G U I D A N C E O N VACC I N E 2 D B A R CO D I N G
|
|
|
- Shon Small
- 7 years ago
- Views:
Transcription
1 Vada Perkins, BSN, MSc, RN CAPT, USPHS, Chief, Business Operations Staff US Food and Drug Administration OV E R V I E W A N D G U I D A N C E O N VACC I N E 2 D B A R CO D I N G "Reviewed April 2013"
2 2D Bar Code Implementation: FDA/CBER Overview for Vaccines 26 Jan 2012 Vada Perkins, CAPT, USPHS Chief, Business Operations Staff FDA/CBER/OD
3 Background Federal Register of February 26, 2004 (69 FR 9120) Bar Code Label Requirements for Human Drug Products and Biological Products Guidance for Industry: Bar Code Label Requirements Questions and Answers (August 2011) [Docket No. FDA 2011 N 0719]-Bar Code Technologies for Drugs and Biological Products; Retrospective Review Under Executive Order
4 Federal Register of February 26, 2004 (69 FR 9120) Final rule requiring certain human drug and biological products to have on their labels a linear bar code that contains, at a minimum, the drug s NDC number (21 CFR ) 4
5 Bar Code Requirements 1 of 2 Drugs approved on or after April 26, 2004, have 60 days from their approval date to comply with the bar code requirement (21 CFR ) All other drugs subject to the bar code requirement, including drugs with applications approved before April 26, 2004, must implement the requirements within 2 years of the effective date (i.e., no later than April 26, 2006) (21 CFR ) 5
6 Bar Code Requirements 2 of 2 A drug manufactured on or after April 26, 2006, must bear a bar code A drug manufactured and distributed by the manufacturer before April 26, 2006, will not need to be recalled or repacked to bear a bar code. 6
7 Linear Bar Code 12 Numeric 7
8 2-Dimensional Bar Codes
9 Appearance of Human Readable Information 9
10 Bar Code Q & A: Q12 FDA will consider requests from vaccine manufacturers who request to use an alternative regulatory program, comprised of alternative technology such as two dimensional symbology, that encodes, for example, the lot number and expiration date, because use of this technology may enhance health care providers ability to keep records and report adverse events as required under the National Childhood Vaccine Injury Act of 1986 (Public Law ) (42 U.S.C. 300aa-25(a)). FDA recognizes that it may be infeasible for a vaccine manufacturer to implement alternate coding technology for childhood vaccines only, while retaining linear bar coding for its other vaccines due to practical considerations related to manufacturing and cost. We will therefore consider a manufacturer s request for such an exemption for other licensed vaccines in addition to childhood vaccines. 10
11 2D Bar Code: CBER Product Office Review
12 2D Bar Code Product Data Elements: CBER Product Office Review 2D bar code to include the following: National Drug Code (can support GTIN) Lot Number Expiration Date *Supports Serialized NDC (sndc) Guidance for Industry: Standards for Securing the Drug-Standardized Numerical Identification for Prescription Drug Packages (Final Guidance) March 2010 Unique alphanumeric identifier (up to 20 characters) NDC + Serial Number 12» m35rtf67h
13 FDA/CBER Labeling Submission: Addition of a 2D Bar Code Industry request: In addition to the current bar code requirements (linear), allow for a 2D Bar Code to be included on existing product labels Prior Approval Supplement (PAS) Labeling Submission Requires review of label and contents Reformatting/placement of label information May consider a CBE (Changes Being Effected) supplement in the future Gather more experience (FDA and Industry) Regulatory approach for CBE vs. PAS submission 13
14 FDA/CBER Review Process: Addition of a 2D Bar Code Review of data elements to be included within the 2D bar code: (Human readable data elements) (NDC, Lot #, Expiration Date) Ensure consistency with NDC assignment at the product and package level (e.g., multilevel packaging). Prescribing Information ( How Supplied section) HL7 Structured Product Labeling (SPL) product data elements Linear bar code Human readable NDC on the carton/container label(s). 14
15 FDA/CBER Review Process Considerations: Addition of a 2D Bar Code 2D barcode size, location, and placement (spacing) Arrangement of the 2D bar code with other content on a label Content structure and format Ensure consistency with a standard (e.g., GS1) Readability 15
16 Equipment/Software/Manufacturing Changes
17 Equipment/Software/Manufacturing Changes Use of existing labeling equipment: Equipment already has the capability for 2-D barcode and will require validation for this addition to the label Annual Report (21 CFR (d)) Applicant needs to add a new labeler Annual Report (21 CFR (d)) 17
18 Equipment/Software/Manufacturing Changes New location (under the existing license) for labeling and packaging CBE-30 in most cases May require an inspection at some point or follow up by Team Biologics A new building on the same site will still be under the same quality systems and therefore reviewing as a supplement may not be required. 18
19 Equipment/Software/Manufacturing Changes: CBER Point of Contact For more information regarding manufacturing changes related to 2D barcode labeling implementation contact: Manufacturers Assistance: Attn: CBER s Division of Manufacturing and Product Quality in the Office of Compliance and Biologics Quality (OCBQ) 19
20 FDA/CBER Review Process: Exemptions
21 Barcode Exemption Request: Bar Code Label Requirements (21 CFR (d)) CBER: Office of Compliance and Biologics Quality (HFM 600), Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, MD CDER: Office of Compliance, Center for Drug Evaluation and Research, Food and Drug Administration, New Hampshire Ave., Bldg. 51, Silver Spring, MD
22 CBER Policy/Procedure: Standard Operating Policies and Procedures (SOPP) Revision to external Labeling SOPP Formalize process for external stakeholders March 2012 (approx.) Internal CBER business processes developed within the product offices for review of 2D barcode submissions 22
23 [Docket No. FDA 2011 N 0719] Bar Code Technologies for Drugs and Biological Products; Retrospective Review Under Executive Order FDA conducting a review of its existing regulations to determine whether they can be made more effective in light of current public health needs and to take advantage of and support advances in innovation Initial comments: 9 January, 2012 Reply comments: 23 February, 2012 Link to Docket: 23 N%252BO%252BSR%252BPS;rpp=10;po=0;D=FDA-2011-N-0719
24 FDA Questions for the Breakout Session 1) What is the structure and format to be incorporated in the 2D barcode (e.g., GS1 standard)? 2) Will 2D barcodes be placed on both the carton and container label(s)? 3) What are the business processes for scanning and recording product to be administered? For example: a) A vaccine supplied as a kit and requires reconstitution -active component to active component -active component to diluent b) Pre-filled syringe 4) What is the data source (drug repository) for the system or systems (if a data source exists)? 5) Have manufacturers confirmed that they are currently in compliance with the bar code rule? 24
25 Thank You Contact Information 25
26 QUESTIONS?
Guidance for Industry Bar Code Label Requirements Questions and Answers
Guidance for Industry Bar Code Label Requirements Questions and Answers For questions on the content of this guidance, contact the Center for Drug Evaluation and Research or the Center for Biologics Evaluation
Guidance for Industry
Guidance for Industry Bar Code Label Requirements Questions and Answers (Question 12 Update) DRAFT GUIDANCE This guidance document is for comment purposes only. Submit comments on this draft guidance by
Guidance for Industry
Guidance for Industry Standards for Securing the Drug Supply Chain - Standardized Numerical Identification for Prescription Drug Packages FINAL GUIDANCE U.S. Department of Health and Human Services Food
Guidance for Industry and Investigators Safety Reporting Requirements for INDs and BA/BE Studies- Small Entity Compliance Guide
Guidance for Industry and Investigators Safety Reporting Requirements for INDs and BA/BE Studies- Small Entity Compliance Guide U.S. Department of Health and Human Services Center for Drug Evaluation and
Guidance for Industry
Guidance for Industry Providing Regulatory Submissions in Electronic Format Content of Labeling U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and
Unique Device Identifier System: Frequently Asked Questions, Vol. 1 Guidance for Industry and Food and Drug Administration Staff
Unique Device Identifier System: Frequently Asked Questions, Vol. 1 Guidance for Industry and Food and Drug Administration Staff Document issued on August 20, 2014. On November 5, 2014 this document was
Guidance Medication Guides Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS)
Guidance s Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS) U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
Guidance for Industry DRAFT GUIDANCE
DSCSA Standards for the Interoperable Exchange of Information for Tracing of Certain Human, Finished, Prescription Drugs: How to Exchange Product Tracing Information Guidance for Industry DRAFT GUIDANCE
Guidance for Industry Classifying Resubmissions in Response to Action Letters
Guidance for Industry Classifying Resubmissions in Response to Action Letters U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center
Guidance for Industry
Guidance for Industry Medication Guides Adding a Toll-Free Number for Reporting Adverse Events U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research
Guidance for Industry Direct-to-Consumer Television Advertisements FDAAA DTC Television Ad Pre- Dissemination Review Program
Guidance for Industry Direct-to-Consumer Television Advertisements FDAAA DTC Television Ad Pre- Dissemination Review Program DRAFT GUIDANCE This guidance document is being distributed for comment purposes
DSCSA Updates and Readiness Check: Requirements for Dispensers and other Trading Partners
DSCSA Updates and Readiness Check: Requirements for Dispensers and other Trading Partners U.S. Food and Drug Administration Center for Drug Evaluation and Research July 2015 Who is a Dispenser? DISPENSER.
National Drug Code Directory
The Drug Listing Act of 1972 requires registered drug establishments to provide the Food and Drug Administration (FDA) with a current list of all drugs manufactured, prepared, propagated, compounded, or
Drug Supply Chain Security Act (Title II of the Drug Quality and Security Act) Overview and Implementation
Drug Supply Chain Security Act (Title II of the Drug Quality and Security Act) Overview and Implementation Connie Jung, RPh, PhD U.S. Food and Drug Administration NACDS Total Store Expo August 24, 2014
Guidance for Industry
Guidance for Industry Charging for Investigational Drugs Under an IND Qs & As DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this
U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) September 2009 OTC
Guidance for Industry Labeling of Nonprescription Human Drug Products Marketed Without an Approved Application as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act: Questions
DSCSA Implementation: Annual Reporting by Prescription Drug Wholesale Distributors and Third-Party Logistics Providers
DSCSA Implementation: Annual Reporting by Prescription Drug Wholesale Distributors and Third-Party Logistics Providers Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for
Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors
Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors FDA Institutional Review Board Inspections Additional copies are available from: Office of Good Clinical Practice Office of Special
Registration of Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act. Guidance for Industry
Registration of Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for
FAQ: Unique Device Identification Final Rule
FAQ: Unique Device Identification Final Rule October 2013 Key Changes from Proposed Rule A separate UDI is not required for devices within a convenience kit, regardless of Class designation, so long as
Guidance for Industry
Guidance for Industry Electronic Source Data in Clinical Investigations U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for
DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Guidance for Industry Fulfilling Regulatory Requirements for Postmarketing Submissions of Interactive Promotional Media for Prescription Human and Animal Drugs and Biologics DRAFT GUIDANCE This guidance
Medical Device Data Systems, Medical Image Storage Devices, and Medical Image
4164-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2014-D-0798] Medical Device Data Systems, Medical Image Storage Devices, and Medical Image Communication Devices;
Guidance for Industry
Guidance for Industry Formal Dispute Resolution: Scientific and Technical Issues Related to Pharmaceutical CGMP U.S. Department of Health and Human Services Food and Drug Administration Center for Drug
Guidance for Industry
Guidance for Industry Electronic Source Data in Clinical Investigations DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft
Guidance for Industry
Guidance for Industry Providing Regulatory Submissions in Electronic Format Drug Establishment Registration and Drug Listing U.S. Department of Health and Human Services Food and Drug Administration Office
Good Review Practice. October 2009 Labeling
Guidance for Industry and Review Staff Labeling for Human Prescription Drug and Biological Products Determining Established Pharmacologic Class for Use in the Highlights of Prescribing Information Good
Guidance for Industry
Guidance for Industry FDA Export Certificates Submit comments and suggestions regarding this document at anytime to Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane,
Medical Devices; Cardiovascular Devices; Classification of the Esophageal Thermal Regulation
This document is scheduled to be published in the Federal Register on 08/18/2015 and available online at http://federalregister.gov/a/2015-20317, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
Guidance for Industry
Guidance for Industry Product Name Placement, Size, and Prominence in Advertising and Promotional Labeling DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments
Risk Evaluation and Mitigation Strategies: Modifications and Revisions Guidance for Industry
Risk Evaluation and Mitigation Strategies: Modifications and Revisions Guidance for Industry The portion of this guidance document setting forth the submission procedures for risk evaluation and mitigation
Guidance for Industry
Guidance for Industry Internet/Social Media Platforms: Correcting Independent Third-Party Misinformation About Prescription Drugs and Medical Devices DRAFT GUIDANCE This guidance document is being distributed
Guidance for Industry
Guidance for Industry Submitting Debarment Certification Statements DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document
Standards for the Interoperable Exchange of Information for Tracing of Human, Finished,
4160-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2014-N-0337] Standards for the Interoperable Exchange of Information for Tracing of Human, Finished, Prescription
Guidance for Clinical Investigators, Sponsors, and IRBs
Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting to IRBs Improving Human Subject Protection U.S. Department of Health and Human Services Office of the Commissioner (OC) Center
Global Unique Device Identification Database (GUDID) Guidance for Industry and Food and Drug Administration Staff
Global Unique Device Identification Database (GUDID) Guidance for Industry and Food and Drug Administration Staff Document issued on June 27, 2014. The draft of this document was issued on September 24,
How To Write A Cer
2014 CBER Update: Advertising & Promotional Labeling Compliance Alpita Popat, PharmD, MBA Consumer Safety Officer Advertising & Promotional Labeling Branch Division of Case Management Office of Compliance
How To Help The Global Healthcare User Group (Hug)
HUG Global Healthcare User Group - HUG GS1 s Brand Architecture 2 The global Healthcare User Group - HUG Mission: Lead the healthcare industry to the effective utilization and development of global standards
By Natalia Wilson, MD, MPH
White Paper The value of unique device identification across healthcare By Natalia Wilson, MD, MPH Executive summary The Unique Device Identification (UDI) System Proposed Rule was published by the U.S.
[DOCKET NO.96N-0002] DRAFT
![[DOCKET NO.96N-0002] DRAFT](/thumbs/26/7603707.jpg "[DOCKET NO.96N-0002] DRAFT")
[DOCKET NO.96N-0002] DRAFT DRAFT DOCUMENT CONCERNING THE REGULATION OF PLACENTAL/UMBILICAL CORD BLOOD STEM CELL PRODUCTS INTENDED FOR TRANSPLANTATION OR FURTHER MANUFACTURE INTO INJECTABLE PRODUCTS DECEMBER,
Unique Device Identification System: Small Entity Compliance Guide Guidance for Industry and Food and Drug Administration Staff
Unique Device Identification System: Small Entity Compliance Guide Guidance for Industry and Food and Drug Administration Staff Document issued on August 13, 2014 On November 5, 2014 this document was
Guidance for Industry Consumer-Directed Broadcast Advertisements
Guidance for Industry Consumer-Directed Broadcast Advertisements U.S. Department of Health and Human Services Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research
Guidance for Industry and FDA Staff FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND Frequently Asked Questions
Guidance for Industry and FDA Staff FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND Frequently Asked Questions U.S. Department of Health and Human Services Food and Drug Administration
Guidance for Industry
Reprinted from FDA s website by EAS Consulting Group, LLC Guidance for Industry Providing Regulatory Submissions in Electronic Format Standardized Study Data DRAFT GUIDANCE This guidance document is being
Agreements and Memoranda of Understanding Between the Food and Drug Administration and
This document is scheduled to be published in the Federal Register on 03/23/2012 and available online at http://federalregister.gov/a/2012-06969, and on FDsys.gov 4160-01-P DEPARTMENT OF HEALTH AND HUMAN
Guidance for Industry
Guidance for Industry Fees-Exceed-the-Costs Waivers Under the Prescription Drug User Fee Act U.S. Department of Health and Human Services Office of Financial Management June 1999 User Fees Guidance for
The Drug Supply Chain Security Act: Readiness and Implementation Update
The Drug Supply Chain Security Act: Readiness and Implementation Update Connie Jung, RPh, PhD U.S. Food and Drug Administration Center for Drug Evaluation and Research Office of Compliance Office of Drug
Unique Device Identification Update FDA and GHTF
Unique Device Identification Update FDA and GHTF Jay Crowley Senior Advisor for Patient Safety Food and Drug Administration jay.crowley@fda.hhs.gov 301-980-1936 UDI Can Improve Visibility Medical device
Application Submitted on Received on Supplement type NDA 021875/S-005 July 24, 2008 July 25, 2008 Changes Being Effected
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 021875/S-005, S-008, S-015 SUPPLEMENT APPROVAL Cephalon Inc. Attention: Paul Kirsch Senior Director and Group
Guidance for Industry and FDA Staff: Current Good Manufacturing Practice Requirements for Combination Products
Guidance for Industry and FDA Staff: Current Good Manufacturing Practice Requirements for Combination Products DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments
Guidance for Industry
Guidance for Industry Toll-Free Number Labeling and Related Requirements for Over-the-Counter and Prescription Drugs Marketed With Approved Applications Small Entity Compliance Guide U.S. Department of
UDI Regulatory 101. Erin (Fields) Quencer. UDI Conference October 28-29, 2014 Baltimore, MD. October 28, 2014. Regulatory Analyst, FDA
UDI Regulatory 101 October 28, 2014 Erin (Fields) Quencer Regulatory Analyst, FDA Slide 1 Basic UDI Requirements Device label and device package must bear a UDI, 21 CFR 801.20 Devices intended to be used
DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Guidance for Industry Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifications DRAFT GUIDANCE This guidance document is being distributed
January 12, 2016. Dear Amy Yang:
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 January 12, 2016 Amy
Guidance for Industry Time and Extent Applications for Nonprescription Drug Products
Guidance for Industry Time and Extent Applications for Nonprescription Drug Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)
ISO Identification of Medicinal Products (IDMP) and HL7 Structured Product Labeling (SPL) Disclaimer
ISO Identification of Medicinal Products (IDMP) and HL7 Structured Product Labeling (SPL) Vada Perkins, CAPT, USPHS US Food and Drug Administration/ Center for Biologics Evaluation and Research 11 October
2D BARCODE STANDARD FOR LENSES (OPTICAL PRODUCT CODE/ COUNTRY OF ORIGIN)
2D BARCODE STANDARD FOR LENSES (OPTICAL PRODUCT CODE/ COUNTRY OF ORIGIN) VOLUNTARY GUIDELINES FOR OPTICAL LENSES September 2012 2012 The Vision Council Developed by: Lens Division of The Vision Council
Use of Electronic Health Record Data in Clinical Investigations
Use of Electronic Health Record Data in Clinical Investigations Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
Guidance for Industry and FDA Staff: Current Good Manufacturing Practice Requirements for Combination Products
Reprinted from FDA s website by EAS Consulting Group, LLC Guidance for Industry and FDA Staff: Current Good Manufacturing Practice Requirements for Combination Products DRAFT GUIDANCE This guidance document
IMPLEMENTATION GUIDELINE
IMPLEMENTATION GUIDELINE Using the GS1 System for U.S. FDA Unique Device Identification (UDI) Requirements F O R S U P P L I E R S & R E C E I V E R S R 1. 1 S E P 1 2 2 0 1 4 CONTENTS PART 1: PREFACE...
Position Paper (II) Healthcare Provider Advisory Council Implementation in hospitals hindered by bar code symbol issues
I. Introduction Towards the end of 2011, GS1 Healthcare established the Healthcare Provider Advisory Council (HPAC) to be the forum for sharing and discussing the practical realities of implementation
Determination of Regulatory Review Period for Purposes of Patent Extension;
This document is scheduled to be published in the Federal Register on 12/15/2015 and available online at http://federalregister.gov/a/2015-31400, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
Implementation manual for barcoding using GS1 global standards for tracing and tracking of pharmaceuticals and drugs for exports
Implementation manual for barcoding using GS1 global standards for tracing and tracking of pharmaceuticals and drugs for exports To facilitate compliance with DGFT Public Notice No. 59(RE-2010)/2009-2014
DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Guidance for Industry Internet/Social Media Platforms with Character Space Limitations Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices DRAFT GUIDANCE This guidance document
Determination of Regulatory Review Period for Purposes of Patent Extension; XARELTO
This document is scheduled to be published in the Federal Register on 05/29/2014 and available online at http://federalregister.gov/a/2014-12349, and on FDsys.gov 4160-01-P DEPARTMENT OF HEALTH AND HUMAN
Use of Nucleic Acid Tests to Reduce the Risk of Transmission of Hepatitis B Virus from Donors
This document is scheduled to be published in the Federal Register on 01/08/2016 and available online at http://federalregister.gov/a/2016-00149, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
Medical Billing and Agency Formal Disputes
Guidance for Industry Formal Dispute Resolution: Appeals Above the Division Level Additional copies of this Guidance are available from: Office of Training and Communications Division of Communications
EHR-IIS 2D Barcode Functional Capabilities Report Version 1.1
EHR-IIS 2D Barcode Functional Capabilities Report Version 1.1 Prepared for Immunization Services Division, National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention
Guidance for Industry Labeling for Bronchodilators: Cold, Cough, Allergy, Bronchodilator,
Reprinted from FDA s website by Guidance for Industry Labeling for Bronchodilators: Cold, Cough, Allergy, Bronchodilator, Guidance And Antiasthmatic for Drug Industry Products for Over-the-Counter Labeling
Guidance for Industry Formal Meetings Between the FDA and Sponsors or Applicants
Guidance for Industry Formal Meetings Between the FDA and Sponsors or Applicants U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)
Contains Nonbinding Recommendations
FY 2016 Medical Device User Fee Small Business Qualification and Certification Guidance for Industry, Food and Drug Administration Staff and Foreign Governments Document issued on August 3, 2015. As of
August 18, 2015. Re: Section 1201 Rulemaking Proposed Exemption for Medical Devices
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 August 18, 2015 Ms. Jacqueline C. Charlesworth General Counsel
April 7, 2015. Acclarent, Inc. Mr. James Patrick Garvey II Sr. Manager, Regulatory Affairs 1525-B O'Brien Drive Menlo Park, CA 94025
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 April 7, 2015 Acclarent,
Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs
Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs Frequently Asked Questions Statement of Investigator (Form FDA 1572) U.S. Department of Health and Human Services Food and Drug
Statement BAR CODE LABEL REQUIREMENTS FOR HUMAN DRUG AND BIOLOGIC PRODUCTS
Statement on BAR CODE LABEL REQUIREMENTS FOR HUMAN DRUG AND BIOLOGIC PRODUCTS Edith Rosato, R.Ph. Vice President Pharmacy Affairs National Association of Chain Drug Stores Alexandria, VA July 26,2002 Submitted
Guidance for Industry
Guidance for Industry Contract Manufacturing Arrangements for Drugs: Quality Agreements DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
Medical Device Labeling Overview
Medical Device Labeling Overview Labeling Task Group IOPP Medical Device Packaging Committee October 22, 2003 Opening Slide Forces that drive the move toward bar codes Device Manufacturers use bar codes
February 2006 Procedural
Guidance for Industry Reports on the Status of Postmarketing Study Commitments Implementation of Section 130 of the Food and Drug Administration Modernization Act of 1997 U.S. Department of Health and
Guidance for Industry
Guidance for Industry Labeling for Human Prescription Drug and Biological Products Implementing the PLR Content and Format Requirements U.S. Department of Health and Human Services Food and Drug Administration
CENTER FOR DRUG EVALUATION AND RESEARCH. 203551Orig1s000
CENTER FOR DRUG EVALUATION AND RESEARCH Approval Package for: APPLICATION NUMBER: Trade Name: Generic Name: Sponsor: 203551Orig1s000 Docetaxel Injection Concentrate, 20 mg/ml, 80 mg/4 ml, 140 mg/7 ml.
NDA 202439/S-008 SUPPLEMENT APPROVAL
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 202439/S-008 SUPPLEMENT APPROVAL Janssen Pharmaceuticals, Inc. ATTENTION: Alla Rhoge Pharm.D., Associate
UDI. Guide to Label and Marking Compliance. Unique Device Identification. For Medical Device Manufacturers
Final Rule UDI Unique Device Identification For Medical Device Manufacturers Guide to Label and Marking Compliance UDI Unique Device Identification Table of Contents Introduction... 1 Compliance with FDA
Guidance for Industry ANDA Submissions Amendments and Easily Correctable Deficiencies Under GDUFA
Guidance for Industry ANDA Submissions Amendments and Easily Correctable Deficiencies Under GDUFA DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions
Biosimilars: Additional Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009
Biosimilars: Additional Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009 Guidance for Industry DRAFT GUIDANCE This guidance document is being
U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) March 2006 Compliance
Guidance for Industry Prescription Drug Marketing Act Donation of Prescription Drug Samples to Free Clinics U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
Providing Regulatory Submissions In Electronic Format Standardized Study Data
Providing Regulatory Submissions In Electronic Format Standardized Study Data Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
Guidance for IRBs, Clinical Investigators, and Sponsors
Guidance for IRBs, Clinical Investigators, and Sponsors IRB Continuing Review after Clinical Investigation Approval U.S. Department of Health and Human Services Food and Drug Administration Center for
Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors
Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors Frequently Asked Questions About Medical Devices Additional copies are available from: Office of Good Clinical Practice Office
Guidance for Industry Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug Inspection
Guidance for Industry Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug Inspection U.S. Department of Health and Human Services Food and Drug Administration Office of Regulatory
Guidance for Review Staff and Industry Good Review Management Principles and Practices for PDUFA Products
Guidance for Review Staff and Industry Good Review Management Principles and Practices for PDUFA Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
American Academy of Pediatrics & GS1 Healthcare US Guideline for Suppliers
ApplicationGuideline American Academy of Pediatrics & GS1 Healthcare US Guideline for Suppliers The Application of GS1 DataMatrix Barcodes to Vaccines for Point of Care Published: February 2012 Contents
EHIMA Guidance Document Revision: V05 Issue date: 2016-01-25
Guidance Document for EHIMA labelling of hearing aids and accessories in accordance with UDI Page 1 of 6 1. Scope This EHIMA guidance document is intended to provide guidance to hearing aid manufacturers
December 31, 2015. comments to the Office of Dietary Supplements (ODS) at the National Institutes of Health on the
December 31, 2015 VIA ELECTRONIC SUBMISSION Richard Bailen, MBA, MHA Office of Dietary Supplements National Institutes of Health 6100 Executive Boulevard, Room 3B01 Bethesda, MD 20892-7517 Email: ODS@nih.gov
Guidance for Industry and FDA Staff
Guidance for Industry and FDA Staff Dear Health Care Provider Letters: Improving Communication of Important Safety Information U.S. Department of Health and Human Services Food and Drug Administration
TITLE 21--FOOD AND DRUGS CHAPTER I--FOOD AND DRUG ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES SUBCHAPTER H--MEDICAL DEVICES
[Code of Federal Regulations] [Title 21, Volume 8] [Revised as of April 1, 2010] [CITE: 21CFR807] TITLE 21--FOOD AND DRUGS CHAPTER I--FOOD AND DRUG ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES
Guidance for IRBs, Clinical Investigators, and Sponsors. Considerations When Transferring Clinical Investigation Oversight to Another IRB
Guidance for IRBs, Clinical Investigators, and Sponsors Considerations When Transferring Clinical Investigation Oversight to Another IRB U.S. Department of Health and Human Services Food and Drug Administration
SUPPORTING STATEMENT. Record Retention Requirements. for the Soy Protein/CHD Health Claim 0910-0428
SUPPORTING STATEMENT Record Retention Requirements for the Soy Protein/CHD Health Claim 0910-0428 A. JUSTIFICATION 1. Necessity of the Information Collection The Federal Food, Drug, and Cosmetic Act (the
Recommended Warning for Overthe-Counter. Containing Drug Products and Labeling Statements Regarding Serious Skin Reactions
Recommended Warning for Overthe-Counter Acetaminophen- Containing Drug Products and Labeling Statements Regarding Serious Skin Reactions Guidance for Industry DRAFT GUIDANCE This guidance document is being
Guidance for Industry
Guidance for Industry IND Exemptions for Studies of Lawfully Marketed Drug or Biological Products for the Treatment of Cancer U.S. Department of Health and Human Services Food and Drug Administration Center